UPC: the Düsseldorf LD on the concept of “imminent infringement”

The Court held that the declared intention to launch a biosimilar drug and the obtaining of the related Marketing Authorization did not constitute an "imminent infringement" of the patent on the originator drug. Therefore, the requested interim injunction was not granted.